ArticleCancers2022

Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study.

Beatrice Casadei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.